Add like
Add dislike
Add to saved papers

Prognostic significance of GSTP1 in patients with triple negative breast cancer.

Oncotarget 2017 September 16
BACKGROUND: Previous studies showed that glutathione S-transferase Pi 1 (GSTP1) is a critical metabolic driver that is heightened specifically in triple negative breast cancer (TNBC) and drives breast cancer pathogenicity. This study focuses on investigating the relationship between the expression of the GSTP1 protein and TNBC metastasis and prognosis in China.

RESULTS: Chi-square and Fisher's exact tests showed that tumor size (P=0.023) and clinical stage (P=0.049) were significantly associated with GSTP1 expression. Patients with high GSTP1 expression exhibited an improved survival rate compared with patients with low GSTP1 expression, but the difference was not statistically significant (P=0.437). On multivariate analysis, clinical stage proved to be an independent prognostic factor for survival in breast cancer.

MATERIALS AND METHODS: A total of 175 patients with histologically confirmed TNBC, who also underwent radical surgery between January 2008 and November 2011 at the Liaoning Cancer Hospital, were enrolled. Immunohistochemistry was used to detect GSTP1 expression in breast cancer tissue from 175 patients. The correlations between GSTP1 expression and other parameters were evaluated using the Chi-square and Fisher's exact tests. Univariate and multivariate Cox regression analyses were performed to assess independent prognostic factors for survival. Associations of GSTP1 expression with clinical stage and prognosis were analyzed using Kaplan-Meier survival curves.

CONCLUSIONS: Tumors with high GSTP1 protein expression were independently associated with low clinical stages in TNBC patients in China. The expression of the GSTP1 protein may be a novel prognosis marker for TNBC patients in China.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app